Abstract: The present invention relates to new aminoindane piperidine compounds, the method of using aminoindane compounds as local anesthetics, said compounds having particularly valuable properties as dermal and topical anesthetics in mammals, including man, as well as compositions containing said compounds.
Type:
Grant
Filed:
June 6, 2000
Date of Patent:
July 2, 2002
Assignee:
Bridge Pharma, Inc.
Inventors:
A. K. Gunnar Aberg, George E. Wright, Jan L. Chen
Abstract: Disclosed are N-substituted metabolites of diphenhydramine, which have been found to be potent and orally active antihistaminic compounds that are devoid of sedative side effects. Phamaceutically acceptable salts of the compounds, a complex with 8-chlorotheo-phylline, therapeutic use and compositions containing the compounds are also described.
Abstract: The S-isomer of a compound represented by the following formula:
and pharmaceutically acceptable salts thereof is disclosed as being useful for treating urinary disorders, including urinary incontinence, and gastrointestinal disorders, including gastrointestinal hyperativity.
Abstract: This invention relates to methods of treatment of ocular disease states, modulated by histaminergic and inflammatory mechanisms in a mammal using norketotifen, 10-OH-norketotifen and pharmaceutical compositions of those compounds. More particularly, this invention relates to methods of treating ocular diseases (such as, seasonal allergic conjunctivitis and other forms of conjunctivitis, keratitis, hyperemia, cellular infiltration, vascularization, fibroblastic proliferation, inflammatory cell degranulation), while avoiding certain side effects, such as local irriation, using compounds with combined antihistaminic and mast cell stabilizing activities.
Abstract: The present invention relates to smooth muscle spasmolytic agents, pharmaceutical compositions containing them and method of using said compounds and compositions for the treatment of urinary incontinence, gastric hyperactivity (ex. Irritable Bowel Syndrome) and other smooth muscle contractile conditions.
More particularly, the present invention relates to certain substituted esters, amides and ketones having smooth muscle relaxing properties while avoiding, on administration to a mammal, adverse side effects such as prominent antimuscarinic, arrhythmogenic and cardiodepressive effects.
Type:
Grant
Filed:
December 23, 1998
Date of Patent:
March 27, 2001
Assignee:
Bridge Pharma, Inc.
Inventors:
A. K. Gunnar Aberg, George E. Wright, Jan L. Chen
Abstract: Disclosed are N-substituted hydroxyalkyl or carboxyalkyloxyalkyl analogs of 9- and/or 10-oxo-4Hbenzo[4,5]cycloheptal[1,2-b]thiophene compounds, or 9-OH and/or 10-OH-substituted analogs thereof, which possess antihistaminic and antiasthmatic properties with reduced sedative side effects. The optically active isomers and pharmaceutically acceptable salts thereof are also described. The compounds were also found to prevent smooth muscle hyperreactivity.
Type:
Grant
Filed:
October 29, 1999
Date of Patent:
March 27, 2001
Assignee:
Bridge Pharma, Inc.
Inventors:
A. K. Gunnar Aberg, George E. Wright, Jan L. Chen
Abstract: A method for treating or preventing urinary incontinence and other motility disorders involving the urethrogenital tract, by administering to a mammal an effective amount of the R-isomers of 4-diethylamino-2-butynyl cyclohexylphenylglycolate and 4-ethylamino-2-butynyl cyclohexylphenylglycolate and pharmaceutically acceptable salts thereof.
Abstract: Method for improving health, survival and muscle growth rate of animals, while reducing carcass fat and improving feed efficiency by administering an optically pure eutomer of an adrenergic beta-2 agonist. The invention is also directed to food compositions comprising the adrenergic beta-2 agonists.